Serum

Drinking apple cider vinegar may help with weight loss but its health benefits are overstated

Retrieved on: 
Wednesday, April 10, 2024
Well, Research, Disease, Overweight, Health, Glucose, Diarrhea, Myocardial infarction, Apple, Cell, Serum, Infection, Appetite, Vegetable, Incidence, Acetic acid, Risk, Physiology, Lipid, Insulin, Diabetes, Weight loss, Internet, Stroke, Blood, Mortality, Cancer, Systematic review, Breakfast, Diet, Cholesterol, Vomiting, Drinking water, Dietary supplement

One day, she explained that she adds apple cider vinegar to improve my health.

Key Points: 
  • One day, she explained that she adds apple cider vinegar to improve my health.
  • Apple cider vinegar is a natural product made of fermented apple juice that has gone sour.
  • I decided to turn medical sleuth and investigate whether apple cider vinegar is as good for health as it sounds.

Claim: disinfectant properties

  • But does apple cider vinegar’s decontaminant qualities translate to the human gut?
  • Our stomachs produce acid, which acts as a natural barrier to infection, so how can adding more acid help?

Claim: weight loss and management of type 2 diabetes

  • There are plenty of anecdotal claims that apple cider vinegar can aid weight loss, supported by limited evidence from several small studies.
  • Apple cider vinegar is thought to cause weight loss through its effect on delay of gastric emptying.
  • Reduced calorific intake will lead to weight loss – but how are the metabolic effects on blood glucose and lipids mediated?
  • In type 2 diabetes there is a reduction in sensitivity to insulin which in turn leads to a reduced uptake of glucose by cells.

Claim: reduces risk of heart disease

  • Raised blood lipids are a risk factor for cardiovascular diseases such as myocardial infarction and stroke.
  • Well, I’m afraid there’s no scientific evidence that vinegar consumption of any kind reduces cardiovascular morbidity and mortality in those with or without diabetes.

Claim: cancer treatment and prevention

  • One of the more outrageous claims of benefits of daily apple cider vinegar consumption is that it may prevent or treat cancer.
  • A frequently quoted case-control study from China found that an increased consumption of vinegar was associated with a reduced incidence of oesophageal cancer.


Stephen Hughes does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

Retrieved on: 
Thursday, April 4, 2024
Diabetes, Disease, Super Meat Boy, Serum, Coronary artery disease, IL-6, Inflammation, Patient, Mortality, Death, NLRP3, ASC, Therapy, Inflammasome, CAD, Pharmaceutical industry

The published data show that inhibiting the NLRP3 inflammasome pathway significantly reduces atherosclerotic lesions and improves hyperglycemic-induced plaque instability.

Key Points: 
  • The published data show that inhibiting the NLRP3 inflammasome pathway significantly reduces atherosclerotic lesions and improves hyperglycemic-induced plaque instability.
  • WESTON, Fla., April 04, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc .
  • (Nasdaq: ZVSA or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights data from a peer-reviewed article published in Biochemical and Biophysical Research Communications.
  • This article demonstrates that NLRP3 inhibition results in improved glucose tolerance and markedly smaller and more stable atherosclerotic lesions in a diabetic mouse model.

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Retrieved on: 
Wednesday, March 27, 2024
Malignancy, Colitis, Survival, BioNTech, Patient, Lung, City, Standard of care, Quality of life, Fungal infection, Aspergillosis, Nationwide, Clinical trial, Bone marrow, Melanoma, Aspergillus fumigatus, Therapy, Human, Psoriasis, Partnership, World Health Organization, Coccidioides, Safety, Clutch (eggs), University, Kidney, Amphotericin B, Neoplasm, Research, Data monitoring committee, Infection, Skin, Vanderbilt University Medical Center, Hospital, Immunodeficiency, FDA, Critical, Element, Toxicity, IL-17A, Brain, Conference call, Conference, Johns Hopkins, Nephrotoxicity, Docetaxel, Serum, Inflammation, Mouse, Mortality, Fusarium, Bangladesh Technical Education Board, Pharmaceutical industry

BEDMINSTER, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports 2023 financial results and provides a business update.

Key Points: 
  • Aspergillus fumigatus is also included in the FDA qualified designation list of pathogens that pose a serious and life-threatening risk.
  • Revenue for 2023 was $1.1 million, which was generated from the Company’s research collaborations with BioNTech SE and Genentech Inc.
  • Cash, cash equivalents and marketable securities as of December 31, 2023 were $13.8 million compared with $28.8 million as of December 31, 2022.
  • Matinas will host a conference call and webcast today beginning at 4:30 p.m. Eastern time.

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Retrieved on: 
Monday, April 8, 2024
Research, FDA, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, JAMA, American Medical Association, Cardiovascular disease, Serum, Patient, Journal, RNA, MD, Therapy, Moyamoya disease, Safety, Small RNA, APOLLO, ASCVD, Pharmaceutical industry

“Positive phase 1 data published in JAMA demonstrate treatment with zerlasiran produced sustained reductions in Lp(a) concentrations with a well-tolerated profile using varying dosing regimens,” said Curtis Rambaran, MD, Chief Medical Officer at Silence and senior author of the publication.

Key Points: 
  • “Positive phase 1 data published in JAMA demonstrate treatment with zerlasiran produced sustained reductions in Lp(a) concentrations with a well-tolerated profile using varying dosing regimens,” said Curtis Rambaran, MD, Chief Medical Officer at Silence and senior author of the publication.
  • Results from the single ascending dose portion of the trial in healthy participants were previously published in the April 2022 issue of JAMA, linked here .
  • Secondary outcomes included the serum levels of zerlasiran and effects on Lp(a) serum concentrations.
  • Zerlasiran is currently being evaluated in the ALPACAR-360 phase 2 study in subjects with baseline Lp(a) levels at or over 125 nmol/L at high risk of ASCVD events.

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Friday, March 22, 2024
SIV, Clinical trial, Hepatitis, Head, CPI, Serum, Hepatitis B, Partnership, HIV, Oncology, Gilead Sciences, Patient, Lung, Journal, Viral load, Pembrolizumab, HBV, Trial of the century, IND, Infection, Hepatocyte, Arenavirus, Antibody, Vaccination, Intellectual property, FDA, Liver, Animal, Pharmaceutical industry

“It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.

Key Points: 
  • “It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.
  • Data was initially presented in May 2023 and additional patient data was provided in October at the European Society for Medical Oncology Congress 2023.
  • HOOKIPA expects to initiate a Phase 1 clinical study of HB-500 in people with HIV in the second quarter of 2024.
  • In June 2023, the Company completed a $50.0 million public offering of common stock and non-voting convertible preferred stock.

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Retrieved on: 
Wednesday, March 20, 2024
Research, Teriparatide, Conference call, Conference, Obesity, Serum, SAN, Weight loss, Female, Adalimumab, Volunteering, Human, Society, Osteoporosis, Workforce, Expansion, Growth, GIP, Business operations, GLP, Animal, HC, Pharmaceutical industry

SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • ET / 1:30 p.m. PT -
    SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended December 31, 2023 and provided a corporate update.
  • In February 2024, Rani announced RT-111 achieved high bioavailability and was well-tolerated, with no serious adverse events in humans, in a Phase 1 study.
  • In December 2023, Rani announced preclinical data demonstrating the transenteric delivery of an incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study.
  • In October 2023, Rani announced preclinical data from a 60-day, repeat oral-administration GLP safety study of the RaniPill capsule in healthy animals.

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer

Retrieved on: 
Monday, March 18, 2024
Ovarian cancer, Mutation, Serum, Patient, Pharming, SGO, Gynecologic Oncology (journal), Platinum, Pharmaceutical industry

Rezatapopt is a first-in-class precision oncology small molecule investigational therapy that selectively targets the TP53 Y220C mutation in solid tumors.

Key Points: 
  • Rezatapopt is a first-in-class precision oncology small molecule investigational therapy that selectively targets the TP53 Y220C mutation in solid tumors.
  • These data were featured today in a late-breaking oral presentation at the 2024 Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer being held March 16-18, 2024 in San Diego, CA.
  • “In this Phase 1 study, we observed promising efficacy of rezatapopt in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation.
  • Our registrational, tumor-agnostic PYNNACLE Phase 2 trial, which includes an ovarian cancer cohort, remains on track to initiate in the first quarter of this year.

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

Retrieved on: 
Wednesday, March 13, 2024
Neurology, Serum, EAE, Multiple sclerosis, ALS, Disease, Patient, Biomarker, Masitinib, Research, Mouse, Science, University, MD, Euronext, Alzheimer's disease, Cytokine, AN, BioRxiv, FDA, NFL, Nerve, FIRST, AFL, NDD, Guideline, Pharmaceutical industry

Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.

Key Points: 
  • Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.
  • The neuroprotective action of masitinib was studied in an animal model of experimental autoimmune encephalitis (EAE).
  • Results showed that masitinib can significantly lower serum NfL levels, and by extension therefore, neuronal damage, in a neuroimmune-driven neurodegenerative disease model, with concomitant reduction in pro-inflammatory cytokines and slowing of clinical symptoms.
  • Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease.

BPGbio Presents Key Advances in its Oncology Pipeline related to the NAi Interrogative Biology Platform

Retrieved on: 
Friday, April 5, 2024
Oncology, Health, Technology, Health Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, UBE2M, Oak Ridge National Laboratory, Neurology, Prostate cancer, Serum, FLNA, Drug discovery, Patient, GBM, Hospital, Research, Cancer, University, Hope, Deep learning, AACR, Clinical trial, Drug development, University of Tennessee, Immune system, Stanford University, Multimedia, Netherlands Architecture Institute

BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico.

Key Points: 
  • BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico.
  • The company will present four posters showcasing these research collaborations and provide updates on other internal research activities at the American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, Calif.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240405006693/en/
    A graphical representation of BPGbio's NAi Interrogative Biology Platform (Graphic: Business Wire)
    New data further validating the mitochondrial-centric effect of BPM31510 on the immune system.

Biological Dynamics Announces Expanding Adoption of ExoVerita™ Pro Under Early Access Program

Retrieved on: 
Tuesday, April 2, 2024
Research, Infectious Diseases, Genetics, Health Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Exosome, EV, Plasma, ACE, Serum, Patient, RNA, DNA, Cancer, Personalized medicine, MD, Fluid mechanics, Doctor of Philosophy, AACR, Genomics, Prognosis, Biology, Centrifuge, Pharmaceutical industry

Biological Dynamics, Inc. , a leader in exosome technology, today announced that Hoag has joined the growing list of customers adopting Biological Dynamics’ ExoVerita Pro instrument, a cost-efficient, automated exosomal enrichment platform.

Key Points: 
  • Biological Dynamics, Inc. , a leader in exosome technology, today announced that Hoag has joined the growing list of customers adopting Biological Dynamics’ ExoVerita Pro instrument, a cost-efficient, automated exosomal enrichment platform.
  • ExoVerita Pro supports exosome-based research efforts, helping to accelerate early disease detection, determine therapeutic response, and more.
  • “Research has shown that exosomes carry important information about human health, but studying them has proven challenging,” said Paul R. Billings, MD, Ph.D., CEO and Chairman of Biological Dynamics.
  • Biological Dynamics will showcase ExoVerita Pro in Booth #4340 at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, Calif., April 5-10.